[Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma].
A case of uterine corpus carcinoma (stage III) after surgical resection of her primary lesion was treated with a medroxyprogesterone acetate (MPA) and PAE (CDDP, adriamycin and etoposide) regimen. The patient has been given MPA during a three-month period and received four courses of PAE regimen. The residual tumor was decreased and removed completely at the second-look operation. Pathologically, the carcinoma cells were clearly changed in loss of atrophy or degeneration by MPA or PAE regimen. After the second-look operation, the patient underwent 4 courses of PAE regimen and was given MPA continuously. We have not recognized any recurrence of carcinoma for seven months after the second look operation.
Tajima
H
H
Dept. of Obstetrics and Gynecology, Saitama Medical School.
Okada
T
T
Fujimori
Y
Y
Tomioka
Y
Y
Hirano
M
M
Yoshida
T
T
Ikeda
S
S
Hata
T
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D012074:Remission Induction; D012086:Reoperation; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D005047:Etoposide; D004317:Doxorubicin; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D002945:Cisplatin